Glenn Begley, M.D., Ph.D. (Amgen Inc. - Thousand Oaks, CA.)
Dr. Begley is the Vice President and Global Head of Hematology and Oncology Research, at Amgen Inc., Thousand Oaks, California. He graduated in medicine from the University of Melbourne in 1978 and continued his training at the Royal Melbourne Hospital and the Walter and Eliza Hall Institute of Medical Research. During his Ph.D. studies, Dr. Begley, in collaboration with Professor Donald Metcalf, identified the human granulocyte colony-stimulating factor (G-CSF) and characterized the G-CSF receptor on normal and leukemic human cells. He has been actively involved in hematopoietic stem cell research and has won numerous awards and has published over 200 papers in scientific and medical journals.
Lee Rosen, M.D. (Premiere Oncology, CA.)
Dr. Rosen is the President and Founder of Premiere Oncology, a center of excellence dedicated to treating cancer by providing comprehensive and holistic clinical care with attention to issues of survivorship and longevity. Dr. Rosen created Premiere Oncology to continue the research he began in 1996 as founder of the Developmental Therapeutics Program at the University of California, Los Angeles (UCLA). He is a principal investigator for many clinical trials focusing on new cancer drug development (Phase I), particularly in the treatment of gastrointestinal malignancies. Dr. Rosen received his Medical Degree from Baylor College of Medicine in Houston, Texas, his B.A. in English Literature from Yale University and Masters of Public Policy (M.P.P.) from Harvard University’s John F. Kennedy School of Government. Please visit http://www.premiereoncology.com/po/ for further information.
Pamela Holland, Ph.D. (Amgen Inc. - Seattle, WA.)
Dr. Holland is a Principal Scientist in Oncology, at Amgen Inc., Seattle, Washington. Amgen is a leading human therapeutics company in the biotechnology industry that strives to serve patients by transforming the promise of science and biotechnology into therapies that have the power to restore health or even save lives. To learn more about Amgen, please visit http://www.amgen.com/ for further information.
Michael Jensen, M.D. (City of Hope, CA)
Dr. Jensen is the Director of the Pediatric Cancer Program, at City of Hope, Duarte California. He graduated from the University of Pennsylvania School of Medicine in 1990 and completed training in Pediatric Hematology and Oncology at the University of Washington/Fred Hutchinson Cancer Research Center. His laboratory work began under the mentorship of Dr. Philip Greenberg, Program Head in Immunology, FHCRC and focused on the immunobiology of tumor-specific T-cells. Dr. Jensen's work focuses on immune-based therapies for treating malignancies, specifically the potential of augmenting the antitumor response of T cells, the body's immune defense against infection and cancerous cells. Please visit http://www.cityofhope.org/directory/people/jensen-michael/Pages/default.aspx for further information.
Calvin Li, Ph.D. (Children’s Hospital of Orange County, CA)
Dr. Li obtained his Ph.D. at the Mount Sinai School of Medicine. His graduate work established a brain neuron protein as a synapse-specific, clathrin coated vesicle-assemble regulator. He has been a pioneer in caveolae-regulated signal transduction research as a postdoctoral fellow supported by NIH-individual national research service award (NRSA) at the Whitehead Institute of the Massachusetts Institute of Technology (M.I.T). As a research fellow at the Harvard University Medical School, he pursued mechanisms of caveolin-mediated signaling events related to cancer. His numerous publications are among the most-frequently-cited research articles as the model system in the caveolae research field. He is an inventor for numerous patent applications. To learn more about Children's Hospital of Orange County, please visit http://www.choc.org/ for further information.